RCT project

Client name

Alexandre Bohyn

Table of contents

1 Descriptive statistics

Table 1: Descriptive statistics of the TRIAL dataset.

| Characteristic	Overall N = 200[1]	Drug A N = 98[1]	Drug B N = 102[1]	p-value[2]
Age at enrollment (years)				0.7
Mean (SD)	47.2 (14.3)	47.0 (14.7)	47.4 (14.0)	
Median (Q1, Q3)	47.0 (38.0, 57.0)	46.0 (37.0, 60.0)	48.0 (39.0, 56.0)	
Unknown	11	7	4	
Biomarker level				0.085
Mean (SD)	0.9 (0.9)	1.0 (0.9)	0.8 (0.8)	
Median (Q1, Q3)	0.6 (0.2, 1.4)	0.8 (0.2, 1.6)	0.5 (0.2, 1.2)	
Unknown	10	6	4	
Tumor stage				0.9
T1	53 (27%)	28 (29%)	25 (25%)	
T2	54 (27%)	25 (26%)	29 (28%)	
T3	43 (22%)	22 (22%)	21 (21%)	
T4	50 (25%)	23 (23%)	27 (26%)	
Tumor grade				0.9
I	68 (34%)	35 (36%)	33 (32%)	
II	68 (34%)	32 (33%)	36 (35%)	
III	64 (32%)	31 (32%)	33 (32%)	
Response to treatment	61 (32%)	28 (29%)	33 (34%)	0.5
Unknown	7	3	4	
Death	112 (56%)	52 (53%)	60 (59%)	0.4
Time to event (days)				0.14
Mean (SD)	19.6 (5.3)	20.2 (5.0)	19.0 (5.5)	
Median (Q1, Q3)	22.4 (15.9, 24.0)	23.5 (17.4, 24.0)	21.2 (14.5, 24.0)	

[1]n (%)

[2]Wilcoxon rank sum test; Pearson's Chi-squared test

2 Survival analysis

Table 2: Cox proportional hazards model results.

Characteristic	HR	95% CI	p-value
Treatment group			0.12
Drug A	—	—	
Drug B	1.36	0.92, 2.01	
Tumor stage			<0.001
T1	—	—	
T2	1.34	0.75, 2.37	
T3	1.30	0.70, 2.42	
T4	2.96	1.69, 5.21	
Tumor grade			0.10
I	—	—	
II	1.25	0.75, 2.06	
III	1.67	1.04, 2.68	
Age at enrollment (years)			0.2
rcs(age, 4)age	1.04	0.98, 1.10	
rcs(age, 4)age'	0.90	0.78, 1.04	
rcs(age, 4)age"	1.62	0.85, 3.09	

Abbreviations: CI = Confidence Interval, HR = Hazard Ratio

Figure 1: Kaplan-Meier curve per treatment group.